PL368306A1 - Preparat o kontrolowanym uwalnianiu klarytromycyny lub tinidazolu - Google Patents
Preparat o kontrolowanym uwalnianiu klarytromycyny lub tinidazoluInfo
- Publication number
- PL368306A1 PL368306A1 PL02368306A PL36830602A PL368306A1 PL 368306 A1 PL368306 A1 PL 368306A1 PL 02368306 A PL02368306 A PL 02368306A PL 36830602 A PL36830602 A PL 36830602A PL 368306 A1 PL368306 A1 PL 368306A1
- Authority
- PL
- Poland
- Prior art keywords
- tinidazol
- clarithromycin
- controlled release
- release formulation
- formulation
- Prior art date
Links
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 title 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title 1
- 229960002626 clarithromycin Drugs 0.000 title 1
- 238000013270 controlled release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960005053 tinidazole Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2001/001564 WO2002017885A2 (en) | 2000-08-29 | 2001-08-29 | Controlled release formulation of erythromycin or a derivative thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL368306A1 true PL368306A1 (pl) | 2005-03-21 |
Family
ID=32259846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02368306A PL368306A1 (pl) | 2001-08-29 | 2002-01-22 | Preparat o kontrolowanym uwalnianiu klarytromycyny lub tinidazolu |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050053657A1 (pl) |
| EP (1) | EP1423097A1 (pl) |
| CN (1) | CN1575164A (pl) |
| BR (1) | BR0212259A (pl) |
| CA (1) | CA2458776A1 (pl) |
| EA (1) | EA200400343A1 (pl) |
| HU (1) | HUP0500791A2 (pl) |
| NO (1) | NO20041196L (pl) |
| PL (1) | PL368306A1 (pl) |
| ZA (1) | ZA200402007B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| CA2592605C (en) * | 2004-12-27 | 2010-12-07 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| EP2283824B1 (en) * | 2009-07-30 | 2017-04-19 | Special Products Line S.p.A. | Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin |
| EP2671571A1 (en) * | 2012-06-05 | 2013-12-11 | Sanovel Ilac Sanayi ve Ticaret A.S. | Controlled-release formulations of clarithromycin |
| CN104042585B (zh) * | 2014-05-21 | 2016-08-24 | 丽珠医药集团股份有限公司 | 一种替硝唑的口服制剂 |
| CN105310990B (zh) * | 2014-12-04 | 2018-01-19 | 蚌埠丰原涂山制药有限公司 | 一种防止粘冲和裂片的对乙酰氨酚片及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4076804A (en) * | 1975-07-18 | 1978-02-28 | Abbott Laboratories | Erythromycin therapy |
| GB1577196A (en) * | 1977-06-03 | 1980-10-22 | Ile De France | Compositions containing erythromycin and metoclopramide |
| US4119723A (en) * | 1977-07-08 | 1978-10-10 | John R. A. Simoons | Treatment of rheumatoid arthritis and related diseases |
| US4331803A (en) * | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4571333A (en) * | 1983-06-14 | 1986-02-18 | Syntex (U.S.A.) Inc. | Controlled release naproxen and naproxen sodium tablets |
| US5200193A (en) * | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
| US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
| US5009897A (en) * | 1988-06-24 | 1991-04-23 | Abbott Laboratories | Pharmaceutical granules and tablets made therefrom |
| US4970081A (en) * | 1989-01-03 | 1990-11-13 | Sterling Drug Inc. | Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
| US6096339A (en) * | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
| US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
| US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| IN186245B (pl) * | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| WO2003024427A1 (en) * | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
-
2002
- 2002-01-22 PL PL02368306A patent/PL368306A1/pl not_active Application Discontinuation
- 2002-01-22 CN CNA028213491A patent/CN1575164A/zh active Pending
- 2002-01-22 EP EP02710212A patent/EP1423097A1/en not_active Withdrawn
- 2002-01-22 EA EA200400343A patent/EA200400343A1/ru unknown
- 2002-01-22 CA CA002458776A patent/CA2458776A1/en not_active Abandoned
- 2002-01-22 US US10/488,112 patent/US20050053657A1/en not_active Abandoned
- 2002-01-22 BR BR0212259-6A patent/BR0212259A/pt not_active IP Right Cessation
- 2002-01-22 HU HU0500791A patent/HUP0500791A2/hu unknown
-
2004
- 2004-03-12 ZA ZA200402007A patent/ZA200402007B/en unknown
- 2004-03-23 NO NO20041196A patent/NO20041196L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200400343A1 (ru) | 2004-08-26 |
| CN1575164A (zh) | 2005-02-02 |
| HUP0500791A2 (en) | 2006-09-28 |
| ZA200402007B (en) | 2004-09-15 |
| EP1423097A1 (en) | 2004-06-02 |
| BR0212259A (pt) | 2004-10-19 |
| NO20041196L (no) | 2004-03-23 |
| US20050053657A1 (en) | 2005-03-10 |
| CA2458776A1 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161996A0 (en) | Directly compressible formulations of azithromycin | |
| GB0218157D0 (en) | Compositions for controlled release | |
| GB2376049B (en) | Controlling activation of devices | |
| IL159048A0 (en) | Sustained release formulation | |
| IL143496A0 (en) | Controlled release formulation comprising gnrh-ii | |
| IL239999A0 (en) | Controlled-release hydrocodone formulations | |
| HUP0401017A3 (en) | Combination of probiotics | |
| EP1581160A4 (en) | ENCAPSULATION PRODUCTS PROVIDING CONTROLLED OR PROLONGED DELIVERY | |
| AU2001286677A1 (en) | Controlled release of substances | |
| HUP0302847A3 (en) | Pharmaceutical formulation comprising bicalutamide | |
| SG84623A1 (en) | Controlled release compositions | |
| EP1372614A4 (en) | SULPHONYL UREA FORMULATION WITH CONTROLLED RELEASE | |
| AU7858401A (en) | Surgical fixings | |
| GB0017468D0 (en) | Silicone release coating compositions | |
| IL161902A0 (en) | Pharmaceutical formulation comprising bicalutamide | |
| AU2001232948A1 (en) | Controlled release of drugs | |
| AU2002351388A1 (en) | Methods and compositions for controlled release of drugs | |
| HUP0204417A3 (en) | Oral ciprofloxacin-composition of controlled release | |
| AU2002337843A8 (en) | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | |
| AU2003300543A1 (en) | Slow release formulation of clarithromycin | |
| EP1620111A4 (en) | FORMULATION OF ERYTHROMYCIN DERIVATIVES WITH CONTROLLED RELEASE | |
| AU2002365136A8 (en) | Compositions and methods for controlled release | |
| GB0125492D0 (en) | Formulation | |
| GB2375048B (en) | Formulation | |
| GB2396812B (en) | Formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |